High dose inhaled salbutamol is increasingly used in the management of chronic obstructive airways disease. To determine the range ofdoses to achieve optimal bronchodilatation and the proportion of patients requiring high dose therapy we have studied 23 patients with chronic obstructive airways disease. Cumulative dose responses were measured to six incremental doses of salbutamol (0. We conclude that in chronic obstructive airways disease there are wide individual variations in the dose of inhaledsalbutamolproducing90% maximalbronchodilatationwithonlyaminorityrequirin bghhdosetherapy.
Introduction
Concern has been expressed over the 'nebulizer epidemic,' but despite this, increasing numbers of patients are being treated with high dose nebulized beta-2 agonists with potential risks from side effects, possible delay in admission to hospital during an acute exacerbation and higher costs.' Patients with severe, largely irreversible airflow limitation form a major group where nebulizer prescriptions are rising rapidly, probably because other therapeutic possibilities are limited.
Starting patients on nebulized salbutamol usually involves an increase in dose from 200 iLg by metered dose inhaler (MDI) to 2.5-5 mg by nebulizer, a 12.5-25-fold increase in dose; whether such large doses arejustified is questionable and the proportion of patients with chronic obstructive airways disease (COAD) who require doses of salbutamol ofgreater than 1 mg to achieve optimal bronchodilatation is unknown. In an open study of 23 patients with COAD, cumulative dose responses to salbutamol have been measured to determine the range of doses required to produce near maximal bronchodilatation and the proportion of such patients who need high dose therapy to achieve this.
Methods
We studied 23 subjects with stable COAD. Table I also shows the numbers of subjects achieving 90% of maximal bronchodilatation with each cumulative dose of salbutamol. It can be seen that there were wide individual variations in the cumulative dose required to produce 90% maximal bronchodilatation and while 5/23 (22%) required more than 1.0 mg the majority 14/23 (61%) achieved 90% maximal bronchodilatation with salbutamol 0.6 mg or less. Analysis ofthe 8 subjects with a baseline FEV, of 1 litre or less showed a similar pattern of response with only two requiring > 1 mg and the majority 6/8 achieving 90% maximal bronchodilatation with salbutamol 0.6 mg or less.
Discussion
These results suggest that most patients with COAD, irrespective of the severity of their disease, achieve 90% maximal bronchodilatation with modest doses of salbutamol (up to 0.6 mg or 6 puffs by MDI) with only a minority gaining additional bronchodilatation from doses ofgreater than 1 mg. This is the first dose-response study to determine the proportion of patients who achieve 'optimal' bronchodilatation with modest doses of inhaled beta-2 agonists in COAD. A number of authors have examined dose responses to beta-2 agonists in asthma, although all have studied only small numbers of subjects. Barnes and Pride reported similar results in asthma with 7/8 subjects achieving maximal bronchodilatation with a cumulative dose of salbutamol of less than 1 mg.2 However, other studies in asthma have suggested that cumulative doses of greater than 2 mg salbutamol3 or 2-5 mg terbutaline4 are required to achieve maximal bronchodilatation. Studies ofsubjects with COAD have tended to show only small improvements in mean parameters of airflow limitation with high dose compared to low dose inhaled beta-2 agonists although higher doses may have a longer duration of effect. [5] [6] [7] [8] A number of points need to be considered in assessing these findings. First, only a minority of our patients had severe airflow limitation (FEVY < 1 litre). Responses of these patients were similar to the group as a whole although, with the possibility of type-2 error in comparing two small groups, caution should be observed in extrapolating to a general population of patients with COAD. Secondly, the choice of 90% maximal bronchodilatation as 'optimal' was arbitrary but is probably a reasonable response to try to achieve in these patients since further bronchodilatation requires disproportionately large increases in dose given the shape ofthe dose response curve. Thirdly, the maximum dose of salbutamol at 1.2 mg was lower than used in some studies; however, mean response had plateaued at 1.0 mg and polynomial regression analysis allowed us to determine maximal bronchodilatation in all subjects. Fourthly, cumulative responses will tend to be greater than response to a single dose because initial bronchodilatation may lead to a more distal subsequent drug penetration;9 patients may therefore benefit from slightly higher doses when taking this in a single administration. Fifthly, duration of response, which may increase with dose, was not assessed;7 8 lower doses may require more frequent administration. Finally, although laboratory tests of short term reversibility have been advocated in selecting patients for a home nebulizer,'0 recent work suggests that they may be poor predictors of long term response." Further studies examining responses to low and high bronchodilators compared to long term response to a home nebulizer would be of interest.
In conclusion, there are wide individual variations in the dose of inhaled salbutamol required to achieve 90% maximal bronchodilatation in patients with COAD. Only a minority require the high doses of salbutamol delivered by nebulizer; doseresponse studies may be of benefit in identifying such patients. 
